Skip to main content

Advertisement

SpringerLink
Log in

Treatment of overactive bladder: what is on the horizon?

  • Review Article
  • Published:
International Urogynecology Journal Aims and scope Submit manuscript

Abstract

There is still a need to develop additional effective and well-tolerated therapies for the treatment of overactive bladder (OAB). The purpose of this review is to discuss alternative therapies for idiopathic OAB that employ a unique mechanism of action or offer a novel application of an existing therapy. We performed a comprehensive literature review to identify alternative therapies and potential future treatments for idiopathic OAB. The use of botulinumtoxin for idiopathic OAB is on the rise and FDA approval will likely be granted in the future. New innovations in neuromodulation hold the promise of less invasive and more patient-controlled therapies. A number of novel medications, such as β-adrenoreceptor agonists, or medications with alternative indications, such as phosphodiesterase inhibitors, have been identified as potential therapies for OAB. In addition, novel drug delivery systems, such as vaginal inserts, are also in development and may provide an attractive mechanism to deliver medications with proven efficacy. While conservative measures such as behavioral modification and pelvic floor exercises remain first-line therapy for OAB, anti-muscarinics are the mainstay of medical treatment. For patients with idiopathic OAB refractory to traditional first-line therapies, a number of promising new treatments are on the horizon.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Haylen BT, de Ridder D, Freeman RM et al (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 21(1):5–26

    Article  PubMed  Google Scholar 

  2. Girman CJ, Jacobsen SJ, Tsukamoto T et al (1998) Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 51:428–436

    Article  PubMed  CAS  Google Scholar 

  3. Stewart WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327–336

    PubMed  CAS  Google Scholar 

  4. Alhasso AA, McKinlay J, Patrick K, Stewart L (2006) Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev (4):CD003193

  5. Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J (2006) Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev (4):CD003781

  6. Khullar V, Cambronero J, Stroberg P et al (2011) The efficacy and tolerability of mirabegron in patients with overactive bladder – results from a European-Australian phase III trial. Eur Urol 10 [Suppl 2]:278

    Google Scholar 

  7. Nitti V, Herschorn S, Auerbach S, Ayers M, Lee M, Martin N (2011) The efficacy and safety of mirabegron with overactive bladder syndrome—results from a North American phase III trial. Eur Urol 10 [Suppl 2]:278

    Google Scholar 

  8. Nitti V, Herschorn S, Auerbach S, Martin N, Blauwet MB, Marshall T (2011) Mirabegron improves patient-reported outcomes in patients with overactive bladder syndrome—results from a North American study. J Urol 185 [Suppl 4]:e784

    Article  Google Scholar 

  9. Chapple CR, Kaplan S, Mitcheson HD et al (2011) Randomized, double-blind, active-controlled phase III study to assess the long-term safety and efficacy of mirabegron in overactive bladder (OAB). Eur Urol 11 [Suppl 1]:683

    Google Scholar 

  10. FDA Advisory Committee Recommends Approval of Mirabegron—Investigational Overactive Bladder Treatment from Astellas. PR Newswire. 5 April 2012. Accessed 30 April 2012. <http://www.prnewswire.com/news-releases/fda-advisory-committee-recommends-approval-of-mirabegron---investigational-overactive-bladder-treatment-from-astellas-146347915.html >

  11. Moore KH, Gilpin SA, Dixon JS, Richmond DH, Sutherst JR (1992) Increase in presumptive sensory nerves of the urinary bladder in idiopathic detrusor instability. Br J Urol 70:370–372

    Article  PubMed  CAS  Google Scholar 

  12. Abdel-Gawad M, Dion SB, Elhilali MM (2001) Evidence of a peripheral role of neurokinins in detrusor hyperreflexia: a further study of selective tachykinin antagonists in chronic spinal injured rats. J Urol 165:1739–1744

    Article  PubMed  CAS  Google Scholar 

  13. Quinn T, Collins C, Baird AW (2004) Mechanisms of neurokinin A- and substance P-induced contractions in rat detrusor smooth muscle in vitro. BJU Int 94:651–657

    Article  PubMed  CAS  Google Scholar 

  14. Lecci A, Giuliani S, Santicioli P, Maggi CA (1994) Involvement of spinal tachykinin NK1 and NK2 receptors in detrusor hyperreflexia during chemical cystitis in anaesthetized rats. Eur J Pharmacol 259:129–135

    Article  PubMed  CAS  Google Scholar 

  15. Doi T, Kamo I, Imai S, Okanishi S, Ikeura Y, Natsugari H (2000) Effects of TAK-637, a tachykinin receptor antagonist, on the micturition reflex in guinea pigs. Eur J Pharmacol 395:241–246

    Article  PubMed  CAS  Google Scholar 

  16. Frenkl TL, Zhu H, Reiss T, Seltzer O, Rosenberg E, Green S (2010) A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder. J Urol 184:616–622

    Article  PubMed  CAS  Google Scholar 

  17. Hougaard C, Fraser MO, Chien C et al (2009) A positive modulator of K Ca 2 and K Ca 3 channels, 4,5-dichloro-1,3-diethyl-1,3-dihydro-benzoimidazol-2-one (NS4591), inhibits bladder afferent firing in vitro and bladder overactivity in vivo. J Pharmacol Exp Ther 328:28–39

    Article  PubMed  CAS  Google Scholar 

  18. Kamiyama Y, Muto S, Masuda H et al (2008) Inhibitory effects of nicorandil, a K ATP channel opener and a nitric oxide donor, on overactive bladder in animal models. BJU Int 101:360–365

    Article  PubMed  CAS  Google Scholar 

  19. Darblade B, Behr-Roussel D, Oger S et al (2006) Effects of potassium channel modulators on human detrusor smooth muscle myogenic phasic contractile activity: potential therapeutic targets for overactive bladder. Urology 68:442–448

    Article  PubMed  Google Scholar 

  20. Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P (2011) Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn 30:556–562

    Article  PubMed  CAS  Google Scholar 

  21. Denys P, Le Normand L, Ghout I et al (2012) Efficacy and Safety of Low Doses of OnabotulinumtoxinA for the Treatment of Refractory Idiopathic Overactive Bladder: A Multicentre, Double-Blind, Randomised, Placebo-Controlled Dose-Ranging Study. Eur Urol 61:520–529

    Article  PubMed  CAS  Google Scholar 

  22. Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D (2011) Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev (12):CD005493

  23. Dmochowski R, Chapple C, Nitti VW et al (2010) Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 184:2416–2422

    Article  PubMed  CAS  Google Scholar 

  24. Kuo HC (2011) Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn 30:1242–1248

    PubMed  Google Scholar 

  25. Botox [package insert]. Allergan, Irvine, CA; November 2011. http://www.allergan.com/assests/pdf/botox_pi.pdf. Accessed 30 April 2012

  26. Yu W, Hill WG, Apodaca G, Zeidel ML (2011) Expression and distribution of transient receptor potential (TRP) channels in bladder epithelium. Am J Physiol Renal Physiol 300:F49–F59

    Article  PubMed  CAS  Google Scholar 

  27. Maggi CA, Barbanti G, Santicioli P et al (1989) Cystometric evidence that capsaicin-sensitive nerves modulate the afferent branch of micturition reflex in humans. J Urol 142:150–154

    PubMed  CAS  Google Scholar 

  28. Juszczak K, Ziomber A, Thor PJ (2011) Effect of partial and complete blockade of vanilloid (TRPV1-6) and ankyrin (TRPA1) transient receptor potential ion channels on urinary bladder motor activity in an experimental hyperosmolar overactive bladder rat model. J Physiol Pharmacol 62:321–326

    PubMed  CAS  Google Scholar 

  29. Miyazato M, Sugaya K, Goins WF et al (2009) Herpes simplex virus vector-mediated gene delivery of glutamic acid decarboxylase reduces detrusor overactivity in spinal cord-injured rats. Gene Ther 16:660–668

    Article  PubMed  CAS  Google Scholar 

  30. Tyagi V, Philips BJ, Su R et al (2009) Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium. J Urol 181:1932–1938

    Article  PubMed  CAS  Google Scholar 

  31. Freeman RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J (2006) The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct 17:636–641

    Article  PubMed  CAS  Google Scholar 

  32. Mukerji G, Yiangou Y, Agarwal SK, Anand P (2010) Increased cannabinoid receptor 1-immunoreactive nerve fibers in overactive and painful bladder disorders and their correlation with symptoms. Urology 75:1514.e15–1514.e20

    Article  Google Scholar 

  33. Truss MC, Stief CG, Uckert S et al (2000) Initial clinical experience with the selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. World J Urol 18:439–443

    Article  PubMed  CAS  Google Scholar 

  34. Takeda H, Yamazaki Y, Igawa Y et al (2002) Effects of beta(3)-adrenoceptor stimulation on prostaglandin E(2)-induced bladder hyperactivity and on the cardiovascular system in conscious rats. Neurourol Urodyn 21:558–565

    Article  PubMed  CAS  Google Scholar 

  35. Kim JC, Park EY, Seo SI, Park YH, Hwang TK (2006) Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol 175:1773–1776, discussion 1776

    Article  PubMed  CAS  Google Scholar 

  36. Tanaka I, Nagase K, Tanase K, Aoki Y, Akino H, Yokoyama O (2010) Improvement in neurogenic detrusor overactivity by peripheral C fiber's suppression with cyclooxygenase inhibitors. J Urol 183:786–792

    Article  PubMed  CAS  Google Scholar 

  37. Ozdemir I, Bozkurt O, Demir O, Aslan G, Esen AA (2009) Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms. Urology 74:431–435

    Article  PubMed  Google Scholar 

  38. Gupta SK, Sathyan G (1999) Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol 39:289–296

    PubMed  CAS  Google Scholar 

  39. Schroder A, Levin RM, Kogan BA, Das AK, Kay F, Mahashabde A (2000) Absorption of oxybutynin from vaginal inserts: drug blood levels and the response of the rabbit bladder. Urology 56:1063–1067

    Article  PubMed  CAS  Google Scholar 

  40. Gittelman M, Reape K, Dasen S, Hait H (2011) A phase 2 study evaluating the safety and efficacy of two doses of a monthly oxybutynin vaginal ring in women with symptoms of overactive bladder. Int Urogynecol J 22 [Suppl 1]:S137

    Google Scholar 

  41. Herbison GP, Arnold EP (2009) Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults. Cochrane Database Syst Rev (2):CD004202

  42. Spinelli M, Malaguti S, Giardiello G, Lazzeri M, Tarantola J, Van Den Hombergh U (2005) A new minimally invasive procedure for pudendal nerve stimulation to treat neurogenic bladder: description of the method and preliminary data. Neurourol Urodyn 24:305–309

    Article  PubMed  Google Scholar 

  43. Peters KM, Feber KM, Bennett RC (2005) Sacral versus pudendal nerve stimulation for voiding dysfunction: a prospective, single-blinded, randomized, crossover trial. Neurourol Urodyn 24:643–647

    Article  PubMed  Google Scholar 

  44. Peters KM, Killinger KA, Boguslawski BM, Boura JA (2010) Chronic pudendal neuromodulation: expanding available treatment options for refractory urologic symptoms. Neurourol Urodyn 29:1267–1271

    Article  PubMed  Google Scholar 

  45. Monga AB, Dmochowski R, Miller D, Altman D (2011) Prospective, randomized clinical trial of a novel, noninvasive, patient-managed neuromodulation system (PMNS) using a sacral patch for the treatment of patients with overactive bladder. Int Urogynecol J 22 (Suppl 1]:S138

    Google Scholar 

  46. De Seze M, Raibaut P, Gallien P et al (2011) Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study. Neurourol Urodyn 30:306–311

    Article  PubMed  Google Scholar 

  47. Amarenco G, Ismael SS, Even-Schneider A et al (2003) Urodynamic effect of acute transcutaneous posterior tibial nerve stimulation in overactive bladder. J Urol 169:2210–2215

    Article  PubMed  CAS  Google Scholar 

  48. Schreiner L, dos Santos TG, Knorst MR, da Silva Filho IG (2010) Randomized trial of transcutaneous tibial nerve stimulation to treat urge urinary incontinence in older women. Int Urogynecol J 21:1065–1070

    Article  PubMed  Google Scholar 

  49. Wheeler JS Jr, Walter JS, Zaszczurynski PJ (1992) Bladder inhibition by penile nerve stimulation in spinal cord injury patients. J Urol 147:100–103

    PubMed  Google Scholar 

  50. Fjorback MV, Rijkhoff N, Petersen T, Nohr M, Sinkjaer T (2006) Event driven electrical stimulation of the dorsal penile/clitoral nerve for management of neurogenic detrusor overactivity in multiple sclerosis. Neurourol Urodyn 25:349–355

    Article  PubMed  Google Scholar 

  51. Goldman HB, Amundsen CL, Mangel J et al (2008) Dorsal genital nerve stimulation for the treatment of overactive bladder symptoms. Neurourol Urodyn 27:499–503

    Article  PubMed  Google Scholar 

  52. Shafik A (1999) A study of the continence mechanism of the external urethral sphincter with identification of the voluntary urinary inhibition reflex. J Urol 162:1967–1971

    Article  PubMed  CAS  Google Scholar 

  53. Nissenkorn I, De Jong PR (2005) A novel surgical technique for implanting a new electrostimulation system for treating female overactive bladder: a preliminary report. BJU Int 95:1253–1258

    Article  PubMed  Google Scholar 

  54. Whiteside JL, Ensrud-Bowlin KM, Wang G, Watschke BP, Roberts KP (2009) Lead placement and associated nerve distribution of an implantable periurethral electrostimulator. Int Urogynecol J Pelvic Floor Dysfunct 20:325–329

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Glickman Urological & Kidney Institute, Cleveland Clinic, Lerner College of Medicine, Cleveland, OH, USA

    Alana M. Murphy, Ryan M. Krlin & Howard B. Goldman

  2. 9500 Euclid Avenue Q10-1, Cleveland, OH, USA

    Alana M. Murphy

Authors
  1. Alana M. Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryan M. Krlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Howard B. Goldman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alana M. Murphy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Murphy, A.M., Krlin, R.M. & Goldman, H.B. Treatment of overactive bladder: what is on the horizon?. Int Urogynecol J 24, 5–13 (2013). https://doi.org/10.1007/s00192-012-1860-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00192-012-1860-6

Keywords

Search

Navigation